Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 28, Number 9—September 2022
Research

Costs of Tuberculosis at 3 Treatment Centers, Canada, 2010–2016

Jonathon R. Campbell, Placide Nsengiyumva, Leslie Y. Chiang, Frances Jamieson, Hadeel Khadawardi, Henry K.-H. Mah, Olivia Oxlade, Hayden Rasberry, Elizabeth Rea, Kamila Romanowski, Natasha F. Sabur, Beate Sander, Aashna Uppal, James C. Johnston, Kevin SchwartzmanComments to Author , and Sarah K. Brode
Author affiliations: McGill University, Montreal, Quebec, Canada (J.R. Campbell, P. Nsengiyumva, O. Oxlade, A. Uppal, K. Schwartzman); Research Institute of the McGill University Health Centre, Montreal (J.R. Campbell, P. Nsengiyumva, H. Rasberry, A. Uppal, K. Schwartzman); McGill International TB Centre, Montreal (J.R. Campbell, O. Oxlade, K. Schwartzman); British Columbia Centre for Disease Control, Vancouver, British Columbia, Canada (L.Y. Chiang, K. Romanowski, J.C. Johnston); University of Toronto, Toronto, Ontario, Canada (F. Jamieson, E. Rea, B. Sander, S.K. Brode); Public Health Ontario, Toronto (F. Jamieson, B. Sander); West Park Healthcare Centre, Toronto (H. Khadawardi, H.K.-H. Mah, N.F. Sabur, S.K. Brode); Toronto Public Health, Toronto (E. Rea); University of British Columbia, Vancouver (K. Romanowski, J.C. Johnston); St. Michael’s Hospital, Toronto (N.F. Sabur); University Health Network, Toronto (B. Sander, S.K. Brode); Montreal Chest Institute, Montreal (K. Schwartzman)

Main Article

Table 4

Duration and costs of drugs used among patients initiating treatment for MDR-TB disease (n = 62) at 3 treatment centers, Canada, July 2010–June 2016*

Drug No. (%) patients receiving drug Median (IQR) duration, mo Cost, 2020 Canadian dollars
Median (IQR) cost per person Mean cost per person
Amikacin 58 (94) 5.1 (2.6–8.2) 4,024 (2,629–8,479) 7,263
Moxifloxacin 58 (94) 19.9 (8–22.4) 809 (318–985) 698
Ethambutol 56 (90) 8.6 (1.1–15.9) 280 (51–637) 382
Pyrazinamide 53 (85) 3.1 (0.8–8.8) 217 (50–800) 545
Clofazimine 50 (81) 19.7 (6.8–22.6) Given under compassionate use
Isoniazid† 47 (76) 0.7 (0.4–1.7) 14 (9–35) 44
Para-amino salicylic acid 47 (76) 13.6 (3.2–20.4) 6,609 (1,917–11,411) 7,036
Rifampin† 46 (74) 0.7 (0.5–1.3) 15 (9–35) 37
Cycloserine 42 (68) 13.4 (7–20.6) 57,658 (28,942–91,935) 61,590
Ethionamide 40 (65) 11.3 (2.8–19.7) 691 (191–1,304) 785
Linezolid 34 (55) 8.4 (3.5–16.2) 10,057 (4,608–19,023) 12,070
Amoxicillin/clavulanate 20 (32) 14.3 (3.9–18.6) 1,144 (286–1,652) 1,524
Imipenem/cilastatin 14 (23) 6.1 (1.8–7.3) 8,459 (3,244–10,267) 7,855
Levofloxacin 13 (21) 11.4 (6.4–18.2) 330 (69–1,328) 1,022
Clarithromycin 10 (16) 16.8 (3.4–21.8) 2,711 (549–3,531) 2,226
Rifabutin 5 (8) 22.9 (22.7–23.7) 13,207 (11,490–13,341) 10,865
Delamanid 4 (6) 3.7 (1.6–6.9) 22,437 (5,616–38,475) 21,654
Azithromycin 3 (5) 9.5 (6.8–13.4) 41 (29–3,850) 2,572
Bedaquiline 3 (5) 5.5 (3.9–5.5) Given under compassionate use
Meropenem 3 (5) 2.1 (1.3–10.2) 21,123 (10,766–75,480) 50,456
Streptomycin 2 (3) 0.7 (0.4–1.1) 980 (512–1,448) 980

*IQR, interquartile range. †Stopped when resistance detected if treatment had been started before MDR TB confirmation.

Main Article

Page created: July 05, 2022
Page updated: August 19, 2022
Page reviewed: August 19, 2022
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external